PMD research array is a comprehensive imputation-aware genotyping resource designed to drive deeper scientific insights into complex disease susceptibility, pharmacogenomics (PGx), and genetic factors underlying wellness and lifestyle.
Features of our test
- Genome-wide association study (GWAS) imputation module with >800,000 markers
- Comprises >5,500 Markers in high-value genes such as APOE (Alzheimer’s disease), BRCA1/2 (breast cancer), DMD (Duchenne muscular dystrophy), and CFTR (cystic fibrosis)
- Accurate genotyping of highly predictive markers in genes including CYP2D6, CYP1A2, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C8 associated with drug metabolism
- Comprises >1,100 blood phenotyping variants for blood typing and bleeding disorders
- Comprise>14,000 immune-related markers (human leukocyte antigen, killer immunoglobulin-like receptors, autoimmune, and inflammatory)
- Comprises 1,149 ADME genes, >5,000 markers from PharmGKB associated with drug metabolism and 92,639 markers in ADME genes, offering the highest density of any commercial array
- Comprises >440 Markers on the Y chromosome that are suitable for applications covering deep ancestry
- Comprises 1,566 markers associated with lifestyle health conditions, most notably obesity, alcohol and smoking addiction, skin conditions, and asthma and allergies
- Comprises >700 Common mitochondrial DNA variants
